The association between symptom burdens and utility in Chinese cancer patients

Quality of Life Research

Volumn 15, Issue 8, 2006, Pages 1427-1438

  Shih, Ya Chen Tina ^a   Wang, Xin Shelley ^a   Cantor, Scott B ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer care; Quality of life; Symptom burdens; Utility assessment

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CANCER STAGING; CHINA; DEMOGRAPHY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DISTRESS SYNDROME; EMOTIONALITY; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM;

AGED; ALGORITHMS; CANCER CARE FACILITIES; CHINA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SATISFACTION; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 33750544915     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-006-0011-2     Document Type: Article

References (31)

1. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276(16) 1339-1341.
2. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276(15) 1253-1258.
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
4. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18(18) 3302-3317.
5. Raiffa H. Decision Analysis: Introductory Lectures on Choices under Uncertainty. New York: Random House, 1968.
6. Cantor SB. Decision analysis: Theory and application to medicine. Prim Care 1995; 22(2) 261-270.
7. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Oper Res 1980; 28: 206-224.
8. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory. Cancer 2000; 89(7) 1634-1646.
9. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomized phase III trail on dose response (CORTC trial 22844). EORTC Radiotherapy Cooperative Group. Eur J Cancer 1998; 34(12) 1902-1909.
10. Kramer JA, Curran D, Piccart M, et al. Randomised trial of paclitaxel vs doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 2000; 36(12) 1488-1497.
11. Wang XS, Wang Y, Guo H, et al. Chinese version of the M. D. Anderson Symptom Inventory: Validation and application of symptom measurement in cancer patients. Cancer 2004; 101(8) 1890-1901.
12. Okuyama T, Wang XS, Akechi T, et al. Japanese version of the M. D. Anderson Symptom Inventory: A validation study. J Pain Symptom Manage 2003; 26(6) 1093-1104.
13. Mystakidou K, Cleeland CS, Tsilika E, et al. Greek MD Anderson Symptom Inventory: Validation and utility in cancer patients. Oncology 2004; 67(3-4) 203-210.
14. Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): Its development and use in a study of cancer pain. Pain 1996; 67(2-3) 407-416.
15. Cleeland CS, Reyes-Gibby CC. When is it justified to treat symptoms? Measuring symptom burden. Oncology 2002; 16(9) 64-70.
16. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51(11) 1115-1128.
17. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21(2) 271-292.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) I Conceptual framework and item selection. Med Care 1992; 30(6) 473-483.
19. Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-related quality of life: A study of Chinese cancer patients. Cancer 1999; 86(9) 1848-1855.
20. Ren XS, Wang XS, Liu S, Hao X. Psychometric and clinical evaluation of the Chinese version of the SF-36 health survey among cancer patients in China. Qual Life Res Newslett 2003; 30: 5-7.
21. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42(9) 851-859.
22. O'Brien BJ, Spath M, Blackhouse G, et al. A review from the bridge: Agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ 2003; 12: 975-981.
23. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5(1) 1-30.
24. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5(4) 559-575.
25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6) 649-655.
26. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res 1993; 2: 477-487.
27. Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: An overview of measurement approaches. J Clin Oncol 2001; 19(1) 220-230.
28. Cleeland CS, Serlin RC, Nakamura Y, et al. Effects of culture and language on ratings of cancer pain and patterns of functional interference. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z (eds.), Progress in Pain Research and Management. Seattle: IASP Press, 1997: 35-51.
29. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
30. Hui EC. The centrality of patient-physician relationship to medical professionalism: An ethical evaluation of some contemporary models. Hong Kong Med J 2005; 11(3) 222-223.
31. Sloan JA, Loprinzi CL, Laurine JA, et al. A simple stratification factor prognostic for survival in advanced cancer: The good/bad/uncertain index. J Clin Oncol 2001; 19(15) 3539-3546.